Home LiteratureArticle Details
PMID: 23990168 Published · ppublish English Journal Article Review

Importance of microbial natural products and the need to revitalize their discovery.

Journal of industrial microbiology & biotechnology ·Vol. 41 ·No. 2 ·2014-02-00 ·Pages 185-201

Demain AL

Abstract

Microbes are the leading producers of useful natural products. Natural products from microbes and plants make excellent drugs. Significant portions of the microbial genomes are devoted to production of these useful secondary metabolites. A single microbe can make a number of secondary metabolites, as high as 50 compounds. The most useful products include antibiotics, anticancer agents, immunosuppressants, but products for many other applications, e.g., antivirals, anthelmintics, enzyme inhibitors, nutraceuticals, polymers, surfactants, bioherbicides, and vaccines have been commercialized. Unfortunately, due to the decrease in natural product discovery efforts, drug discovery has decreased in the past 20 years. The reasons include excessive costs for clinical trials, too short a window before the products become generics, difficulty in discovery of antibiotics against resistant organisms, and short treatment times by patients for products such as antibiotics. Despite these difficulties, technology to discover new drugs has advanced, e.g., combinatorial chemistry of natural product scaffolds, discoveries in biodiversity, genome mining, and systems biology. Of great help would be government extension of the time before products become generic.

MeSH Terms
Anti-Bacterial Agents/metabolism Antineoplastic Agents/metabolism Biological Products/metabolism,pharmacology Drug Discovery Genome, Microbial Immunosuppressive Agents/metabolism Secondary Metabolism/genetics
Chemicals
Anti-Bacterial Agents Antineoplastic Agents Biological Products Immunosuppressive Agents
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Demain Arnold L
Research Institute for Scientists Emeriti (R.I.S.E.), Drew University, Madison, NJ, 07940, USA, ademain@drew.edu.
References (98)
98 references, click to expand
  1. Efficient synthesis of simvastatin by use of whole-cell biocatalysis.
    Appl Environ Microbiol. 2007 Apr;73(7):2054-60 PMID: 17277201
  2. Taxol from Tubercularia sp. strain TF5, an endophytic fungus of Taxus mairei.
    FEMS Microbiol Lett. 2000 Dec 15;193(2):249-53 PMID: 11111032
  3. Studies in the biochemistry of micro-organisms. 86. The molecular constitution of mycophenolic acid, a metabolic product of Penicillium Brevi-compactum Dierckx. Part III. Further observations on the structural formula for mycophenolic acid.
    Biochem J. 1952 Mar;50(5):630-4 PMID: 14934668
  4. Antibiotic resistance in bacteria and its future for novel antibiotic development.
    Biosci Biotechnol Biochem. 2006 May;70(5):1060-75 PMID: 16717405
  5. Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity.
    Biochemistry. 2008 Apr 15;47(15):4501-9 PMID: 18355043
  6. From natural products discovery to commercialization: a success story.
    J Ind Microbiol Biotechnol. 2006 Jul;33(7):486-95 PMID: 16402247
  7. Natural product guided compound library development.
    Curr Med Chem. 2002 Dec;9(23):2129-45 PMID: 12470251
  8. Infectious history.
    Science. 2000 Apr 14;288(5464):287-93 PMID: 10777411
  9. Multidrug resistance reversal agents.
    J Med Chem. 2003 Nov 6;46(23):4805-17 PMID: 14584929
  10. Mining and engineering natural-product biosynthetic pathways.
    Nat Chem Biol. 2007 Jul;3(7):379-86 PMID: 17576425
  11. Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors.
    Expert Opin Investig Drugs. 2001 Feb;10(2):269-80 PMID: 11178340
  12. History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents.
    Curr Pharm Biotechnol. 2012 May;13(6):853-65 PMID: 22039784
  13. Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew.
    Science. 1993 Apr 9;260(5105):214-6 PMID: 8097061
  14. Lantibiotics: diverse activities and unique modes of action.
    J Biosci Bioeng. 2009 May;107(5):475-87 PMID: 19393544
  15. Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders.
    Expert Opin Investig Drugs. 2000 Oct;9(10):2331-42 PMID: 11060810
  16. Cineromycins, gamma-butyrolactones and ansamycins by analysis of the secondary metabolite pattern created by a single strain of Streptomyces.
    J Antibiot (Tokyo). 1999 Jul;52(7):635-42 PMID: 10513843
  17. Antimicrobials, drug discovery, and genome mining.
    Appl Microbiol Biotechnol. 2013 Feb;97(3):969-78 PMID: 23233204
  18. What's new on the antimicrobial horizon?
    Int J Antimicrob Agents. 2008 Dec;32 Suppl 4:S207-13 PMID: 19134521
  19. Antibiotics--an investment worth making?
    Nat Biotechnol. 2006 Dec;24(12):1512-4 PMID: 17160052
  20. A new class of cyclosporin analogues for the treatment of asthma.
    Expert Opin Investig Drugs. 2003 Apr;12(4):647-53 PMID: 12665419
  21. 2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery.
    J Med Chem. 2002 Dec 19;45(26):5609-16 PMID: 12477342
  22. Marine actinomycete diversity and natural product discovery.
    Antonie Van Leeuwenhoek. 2005 Jan;87(1):43-8 PMID: 15726290
  23. Fungal secondary metabolites - strategies to activate silent gene clusters.
    Fungal Genet Biol. 2011 Jan;48(1):15-22 PMID: 20433937
  24. From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries.
    Angew Chem Int Ed Engl. 2002 Aug 16;41(16):2879-90 PMID: 12203413
  25. A review of Judah Folkman's remarkable achievements in biomedicine.
    Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13203-5 PMID: 18772371
  26. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
    Nature. 2002 Nov 7;420(6911):78-84 PMID: 12422218
  27. Antitumor polyketide biosynthesis by an uncultivated bacterial symbiont of the marine sponge Theonella swinhoei.
    Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16222-7 PMID: 15520376
  28. Combinatorial biosynthesis of polyketides--a perspective.
    Curr Opin Chem Biol. 2012 Apr;16(1-2):117-23 PMID: 22342766
  29. Characterization of protein Ser/Thr phosphatases of the malaria parasite, Plasmodium falciparum: inhibition of the parasitic calcineurin by cyclophilin-cyclosporin complex.
    Mol Biochem Parasitol. 1999 Apr 30;99(2):167-81 PMID: 10340482
  30. A multiplasmid approach to preparing large libraries of polyketides.
    Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11740-5 PMID: 10518520
  31. Antibiotic-producing ability by representatives of a newly discovered lineage of actinomycetes.
    Microbiology (Reading). 2006 Mar;152(Pt 3):675-683 PMID: 16514148
  32. Genetically engineered analogs of ascomycin for nerve regeneration.
    J Pharmacol Exp Ther. 2002 Sep;302(3):1278-85 PMID: 12183690
  33. Bartolomeo Gosio, 1863-1944: an appreciation.
    Adv Appl Microbiol. 2001;48:229-50 PMID: 11677681
  34. Genomic mining for Aspergillus natural products.
    Chem Biol. 2006 Jan;13(1):31-7 PMID: 16426969
  35. New natural epothilones from Sorangium cellulosum, strains So ce90/B2 and So ce90/D13: isolation, structure elucidation, and SAR studies.
    J Nat Prod. 2001 Jul;64(7):847-56 PMID: 11473410
  36. Biomedicinals from the phytosymbionts of marine invertebrates: a molecular approach.
    Methods. 2007 Aug;42(4):358-76 PMID: 17560324
  37. Bioreactor studies on the endophytic fungus Entrophospora infrequens for the production of an anticancer alkaloid camptothecin.
    Can J Microbiol. 2006 Mar;52(3):189-96 PMID: 16604115
  38. Combinatorial biosynthesis of cyclic lipopeptide antibiotics: a model for synthetic biology to accelerate the evolution of secondary metabolite biosynthetic pathways.
    ACS Synth Biol. 2014 Oct 17;3(10):748-58 PMID: 23654258
  39. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells.
    Sci Transl Med. 2011 Jun 29;3(89):89ra58 PMID: 21715679
  40. A guide to drug discovery: Target selection in drug discovery.
    Nat Rev Drug Discov. 2003 Jan;2(1):63-9 PMID: 12509760
  41. Rainforest endophytes and bioactive products.
    Crit Rev Biotechnol. 2002;22(4):315-33 PMID: 12487423
  42. Curing metastatic testicular cancer.
    Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4592-5 PMID: 11904381
  43. Improving simvastatin bioconversion in Escherichia coli by deletion of bioH.
    Metab Eng. 2007 Jul;9(4):379-86 PMID: 17625941
  44. Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs.
    Appl Microbiol Biotechnol. 2002 Apr;58(5):555-64 PMID: 11956737
  45. Camptothecin and taxol: from discovery to clinic.
    J Ethnopharmacol. 1996 Apr;51(1-3):239-53; discussion 253-4 PMID: 9213622
  46. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.
    Nat Med. 2002 Feb;8(2):128-35 PMID: 11821896
  47. Ivermectin: 25 years and still going strong.
    Int J Antimicrob Agents. 2008 Feb;31(2):91-8 PMID: 18037274
  48. Contributions of microorganisms to industrial biology.
    Mol Biotechnol. 2008 Jan;38(1):41-55 PMID: 18060538
  49. Shikonin, acetylshikonin, and isobutyroylshikonin inhibit VEGF-induced angiogenesis and suppress tumor growth in lewis lung carcinoma-bearing mice.
    Yakugaku Zasshi. 2008 Nov;128(11):1681-8 PMID: 18981704
  50. Biosynthesis of rapamycin and its regulation: past achievements and recent progress.
    J Antibiot (Tokyo). 2010 Aug;63(8):434-41 PMID: 20588302
  51. Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
    J Med Chem. 2009 Oct 8;52(19):6053-61 PMID: 19791806
  52. Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin.
    Antimicrob Agents Chemother. 2000 Jan;44(1):143-9 PMID: 10602736
  53. Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica.
    Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10376-81 PMID: 17563368
  54. Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
    J Nat Prod. 2001 Feb;64(2):265-77 PMID: 11430019
  55. Plants and human health in the twenty-first century.
    Trends Biotechnol. 2002 Dec;20(12):522-31 PMID: 12443874
  56. Prescription for an ailing pharmaceutical industry.
    Nat Biotechnol. 2002 Apr;20(4):331 PMID: 11923826
  57. Novel cytotoxic agents: epothilones.
    Am J Health Syst Pharm. 2008 May 15;65(10 Suppl 3):S10-5 PMID: 18463327
  58. Quinolone, everninomycin, glycylcycline, carbapenem, lipopeptide and cephem antibacterials in clinical development.
    Curr Med Chem. 2001 Dec;8(14):1775-93 PMID: 11562293
  59. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.
    J Antibiot (Tokyo). 1975 Oct;28(10):721-6 PMID: 1102508
  60. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.
    Proc Natl Acad Sci U S A. 1980 Jul;77(7):3957-61 PMID: 6933445
  61. Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR.
    Antimicrob Agents Chemother. 2001 Nov;45(11):3162-70 PMID: 11600372
  62. HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein.
    Am J Health Syst Pharm. 2004 Aug 15;61(16):1676-81 PMID: 15540478
  63. A two component-type cytochrome P-450 monooxygenase system in a prokaryote that catalyzes hydroxylation of ML-236B to pravastatin, a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
    Biochim Biophys Acta. 1991 Jun 19;1084(1):35-40 PMID: 1905157
  64. Production and purification of statins from Pleurotus ostreatus (Basidiomycetes) strains.
    Z Naturforsch C J Biosci. 2003 Jan-Feb;58(1-2):62-4 PMID: 12622228
  65. A genomics-guided approach for discovering and expressing cryptic metabolic pathways.
    Nat Biotechnol. 2003 Feb;21(2):187-90 PMID: 12536216
  66. Antibiotics at the crossroads.
    Nature. 2004 Oct 21;431(7011):899-902 PMID: 15496893
  67. Antineoplastic agents from natural sources: achievements and future directions.
    Expert Opin Investig Drugs. 2000 Dec;9(12):2783-97 PMID: 11093353
  68. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity.
    FEBS Lett. 1976 Dec 31;72(2):323-6 PMID: 16386050
  69. Plasticity of the streptomyces genome-evolution and engineering of new antibiotics.
    Curr Med Chem. 2005;12(14):1697-704 PMID: 16022666
  70. Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics.
    Curr Opin Microbiol. 2008 Oct;11(5):401-8 PMID: 18848642
  71. Chasing the treasures of the sea - bacterial marine natural products.
    Curr Opin Microbiol. 2009 Jun;12(3):252-60 PMID: 19481972
  72. Big effects from small changes: possible ways to explore nature's chemical diversity.
    Chembiochem. 2002 Jul 2;3(7):619-27 PMID: 12324995
  73. Back to basics: how natural products can provide the basis for new therapeutics.
    Expert Opin Investig Drugs. 2007 Nov;16(11):1753-73 PMID: 17970636
  74. The TOR signaling cascade regulates gene expression in response to nutrients.
    Genes Dev. 1999 Dec 15;13(24):3271-9 PMID: 10617575
  75. Systems biology of antibiotic production by microorganisms.
    Nat Prod Rep. 2007 Dec;24(6):1262-87 PMID: 18033579
  76. Camptothecin, over four decades of surprising findings.
    Phytochemistry. 2004 Oct;65(20):2735-49 PMID: 15474560
  77. Search and discovery strategies for biotechnology: the paradigm shift.
    Microbiol Mol Biol Rev. 2000 Sep;64(3):573-606 PMID: 10974127
  78. Nonribosomal peptide synthetases involved in the production of medically relevant natural products.
    Mol Pharm. 2008 Mar-Apr;5(2):191-211 PMID: 18217713
  79. Ascomycins: promising agents for the treatment of inflammatory skin diseases.
    Expert Opin Investig Drugs. 2000 Jan;9(1):69-77 PMID: 11060661
  80. Investing in green and white biotech.
    Nat Biotechnol. 2006 Jul;24(7):765-7 PMID: 16841055
  81. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum.
    J Chem Soc Perkin 1. 1976;(11):1165-70 PMID: 945291
  82. Studies on the biosynthesis of epothilones: the biosynthetic origin of the carbon skeleton.
    J Antibiot (Tokyo). 2000 Dec;53(12):1373-7 PMID: 11217802
  83. The TOR kinases link nutrient sensing to cell growth.
    J Biol Chem. 2001 Mar 30;276(13):9583-6 PMID: 11266435
  84. A historical perspective on the discovery of statins.
    Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(5):484-93 PMID: 20467214
  85. Genetic engineering of macrolide biosynthesis: past advances, current state, and future prospects.
    Appl Microbiol Biotechnol. 2010 Feb;85(5):1227-39 PMID: 19902203
  86. Natural products as sources of new drugs over the period 1981-2002.
    J Nat Prod. 2003 Jul;66(7):1022-37 PMID: 12880330
  87. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis.
    Science. 2009 Feb 27;323(5918):1215-8 PMID: 19251630
  88. Antifungal proteins.
    Appl Environ Microbiol. 2001 Jul;67(7):2883-94 PMID: 11425698
  89. Cancer risk in people infected with human immunodeficiency virus in the United States.
    Int J Cancer. 2008 Jul 1;123(1):187-94 PMID: 18435450
  90. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei.
    Antimicrob Agents Chemother. 2003 Mar;47(3):956-64 PMID: 12604527
  91. Prodigiosins: a novel family of immunosuppressants with anti-cancer activity.
    Indian J Biochem Biophys. 2007 Oct;44(5):295-302 PMID: 18341204
  92. Antibiotics: where did we go wrong?
    Drug Discov Today. 2005 Jan 1;10(1):45-52 PMID: 15676298
  93. Statins: the new aspirin?
    Cell Mol Life Sci. 2002 Nov;59(11):1771-86 PMID: 12530513
  94. Production of 'hybrid' antibiotics by genetic engineering.
    Nature. 1985 Apr 18-24;314(6012):642-4 PMID: 3857464
  95. Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase.
    J Antibiot (Tokyo). 1980 Mar;33(3):334-6 PMID: 7380744
  96. Mother nature's combinatorial libraries; their influence on the synthesis of drugs.
    Curr Opin Drug Discov Devel. 2002 Mar;5(2):304-16 PMID: 11926137
  97. Genetic engineering of taxol biosynthetic genes in Saccharomyces cerevisiae.
    Biotechnol Bioeng. 2006 Feb 5;93(2):212-24 PMID: 16161138
  98. Taxol from Phyllosticta citricarpa, a leaf spot fungus of the angiosperm Citrus medica.
    J Biosci Bioeng. 2008 Jul;106(1):103-6 PMID: 18691540
Article Info
Journal
Journal of industrial microbiology & biotechnology
Abbr.
J Ind Microbiol Biotechnol
ISSN
1476-5535
Published
2014-02-00
Epub
2013-00-30
Pages
185-201
Language
English
Region
Germany
NLM ID
9705544
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com